Editas Medicine stock has November 9, 2026 earnings date
Published on 10/15/2026 at 19:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSScheduled date and valuation
- Editas Medicine is scheduled to report earnings on November 9, 2026.
- Second-quarter revenue reached USD 11.89 million, compared with USD 2.83 million in the first quarter.
- Editas Medicine stock costs EUR 2.14 at Lang & Schwarz on October 15, 2026 at 7:14 p.m. CEST.
- The company had a market capitalization of USD 367.8 million and a P/E ratio of minus 3.20.
Editas Medicine is scheduled to report its next earnings on November 9, 2026, according to InsiderBuying. The biotech company is developing CRISPR-based genomic medicines, while its Nasdaq-listed stock was trading at EUR 2.14 at Lang & Schwarz on October 15, 2026 at 7:14 p.m. CEST.
Revenue provides the operating marker
Editas reported USD 11.89 million in revenue for the second quarter of 2026, compared with USD 2.83 million in the first quarter. The company also recorded a net loss attributable to common shareholders of USD 18.23 million and diluted earnings per share of minus USD 0.15 for the second quarter, according to MarketBeat.
Stock stays within its yearly range
The primary Nasdaq quote stood at USD 2.40 on October 15, 2026 at 1:24 p.m. ET. The 52-week range was USD 1.66 to USD 4.33, while the market capitalization was USD 367.8 million. Average trading volume was 2.52 million shares, against current volume of 882,893 shares.
Editas had USD 181.8 million in cash on June 30, 2026, while operating cash flow for the second quarter was negative USD 29.6 million. The company develops therapies for genetic diseases, including programs aimed at hyperlipidemia and blood disorders.
Comparison with peers
Editas Medicine (Nasdaq, USD): P/E minus 3.20, market capitalization USD 367.8 million.
CRISPR Therapeutics (Nasdaq, USD): daily change 2.42 percent, market capitalization USD 5.0 billion.
Intellia Therapeutics (Nasdaq, USD): daily change 2.41 percent, market capitalization USD 1.6 billion.
Price and reporting date
The November 9, 2026 reporting date gives investors the next scheduled company milestone. The second-quarter revenue figure and cash position provide the main operating markers ahead of that date. The Nasdaq quote and the euro quotation are separate venue observations.
The stock was trading at EUR 2.14 at Lang & Schwarz on October 15, 2026 at 7:14 p.m. CEST. The primary Nasdaq quote stood at USD 2.40 on October 15, 2026 at 1:24 p.m. ET.
The further course of trading is shown by the continuously updated real-time quote of Editas Medicine stock.
Editas Medicine market data
- Company: Editas Medicine, Inc.
- ISIN: US28106W1036
- Ticker: EDIT
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 15, 2026, 7:14 p.m. CEST): EUR 2.14
- Market capitalization: USD 367.8 million (as of October 15, 2026)
- 52-week range: USD 1.66-4.33 (as of October 15, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 9, 2026
Market context: Market report S&P 500.
